Bladder cancer gets a targeted attack: new micelle therapy enters human trials

NCT ID NCT06173349

Recruiting now Disease control Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

First seen Mar 15, 2026 · Last updated May 12, 2026 · Updated 5 times

Summary

This early-stage trial tests a new treatment called PPM for people with a type of bladder cancer that has returned or not responded to standard therapy. PPM uses tiny particles (micelles) coated with a targeting molecule to deliver a chemotherapy drug directly to cancer cells in the bladder, aiming to kill them while reducing side effects. The study will enroll about 12 participants to check safety and see if the tumors shrink or disappear.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE 0A BLADDER CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of California Davis Comprehensive Cancer Center
RECRUITING

Sacramento, California, 95817, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

RECURRENT NON-MUSCLE INVASIVE BLADDER CARCINOMA STAGE 0A BLADDER CANCER AJCC V8 STAGE 0A BLADDER CANCER AJCC V8 STAGE 0IS BLADDER CANCER AJCC V8 STAGE 0IS BLADDER CANCER AJCC V8 STAGE I BLADDER CANCER AJCC V8 STAGE I BLADDER CANCER AJCC V8